 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM...

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update PR Newswire CUPERTINO, Calif., Aug. 9, 2023 - Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from...

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

Earnings Outlook For Durect

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., Aug. 3, 2023 CUPERTINO, Calif., Aug. 3, 2023 /PRNewswire/ --DURECT...

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire CUPERTINO, Calif., July 20, 2023 CUPERTINO, Calif., July 20, 2023...

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

For the last three days, A.I.dvisor has detected that DRRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for DRRX, and traders may view it as a Sell signal for the next month. Traders may consider ...

DURECT (DRRX, $4.85) Aroon Indicator entered a Downtrend on July 10, 2023.

This is a signal that DRRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

DURECT (DRRX, $5.02) Stochastic Oscillator left the oversold zone on July 07, 2023

DURECT (DRRX, $5.02) Aroon Indicator entered a Downtrend on July 07, 2023.

DURECT (DRRX, $4.9) Aroon Indicator entered a Downtrend on July 05, 2023.

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Watchers	8,377
52-Wk Low	$2.67
52-Wk High	$9.50

Market Cap	$77.83M
Volume (M)	71,270.00
52-Wk High	$9.50
52-Wk Low	$2.67

Current Price	$2.73
Prev Close	$2.82
Open	$2.81
Dividend Yield	0.00%
50-Day Moving Average	$3.34
Beta	1.07
Avg. Volume	172,869.57
PE Ratio	-1.84

52-Week High	$9.50
52-Week Low	$2.67
Market Capitalization	$77.83M
EPS	-$1.53
Price to Book	12.62
Revenue Per Employee	$245,911.39
Enterprise Value/EBITDA	-3.16

DRRX Durect Corp

About

Feed

News

Sentiment

Earnings

Fundamentals